Capmatinib

ATC L01EP01 · 8 markets · 17 records

Capmatinib 8 markets · 17 records Forms

US 4 records · 2 strengths

200 mgtabletTABRECTA+1Manufacturer: Novartis Pharma Produktions… also in CA·SG·ES +1
150 mgtabletTABRECTA+1Manufacturer: Novartis Pharma Produktions… also in CA·SG·ES +1

CA 2 records · 2 strengths

200 mgtabletTABRECTA also in US·SG·ES +1
150 mgtabletTABRECTA also in US·SG·ES +1

AU 2 records · 2 strengths

244 mgtabletTABRECTA capmatinib (as hydrochloride) 150 mg tablet blister pack unknown
183 mgtabletTABRECTA capmatinib (as hydrochloride) 150 mg tablet blister pack unknown

SG 2 records · 2 strengths

200 mgtabletTABRECTA also in US·CA·ES +1
150 mgtabletTABRECTA also in US·CA·ES +1

ES 2 records · 2 strengths

200 mgtabletTABRECTA also in US·CA·SG +1
150 mgtabletTABRECTA also in US·CA·SG +1

TW 2 records · 2 strengths

200 mgtabletTABRECTA+1泰芮塔200毫克膜衣錠 also in US·CA·SG +1
150 mgtabletTABRECTA+1泰芮塔150毫克膜衣錠 also in US·CA·SG +1

HK 2 records · 1 strengths

2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商

With a brand name Con nombre comercial 有商品名有商品名TABRECTA ×16

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包完整清單見資料包

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商

With a brand name Con nombre comercial 有商品名有商品名TABRECTA ×8

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包完整清單見資料包

Side-by-side table

Strength / form / release	US	CA	AU	SG	ES	TW	HK	EU
200 mg tablet	Manufacturer: Novartis Pharma Produktions… ×2 TABRECTA	TABRECTA	not recorded	TABRECTA	TABRECTA	TABRECTA 泰芮塔200毫克膜衣錠	not recorded	not recorded
150 mg tablet	Manufacturer: Novartis Pharma Produktions… ×2 TABRECTA	TABRECTA	not recorded	TABRECTA	TABRECTA	TABRECTA 泰芮塔150毫克膜衣錠	not recorded	not recorded
244 mg tablet	not recorded	not recorded	TABRECTA capmatinib (as hydrochloride) 150 mg tablet blister pack	not recorded	not recorded	not recorded	not recorded	not recorded
183 mg tablet	not recorded	not recorded	TABRECTA capmatinib (as hydrochloride) 150 mg tablet blister pack	not recorded	not recorded	not recorded	not recorded	not recorded
not disclosed unknown	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded	TABRECTA	TABRECTA

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

1 more strength/form rows are recorded only in HK · EU and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en HK · EU que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 HK · EU 有记录（未在本表显示）。另有 1 個規格/劑型僅在 HK · EU 有記錄（未在本表顯示）。

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.

Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.